Current Report Filing (8-k)
16 March 2018 - 8:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 15, 2018 (March 9, 2018)
|
|
|
|
NewLink Genetics Corporation
|
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
001-35342
|
42-1491350
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
|
2503 South Loop Drive
Ames, IA
|
50010
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant's telephone number, including area code:
(515) 296-5555
|
|
Not applicable
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act
o
Section 5 - Corporate Governance and Management
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Executive Officer Equity Awards and Goals
Effective March 9, 2018, the Board of Directors (the “
Board
”) of NewLink Genetics Corporation (the “
Company
”) approved 2018 compensation for the named executive officers for the 2018 fiscal year with respect to stock option awards. The Board also set corporate and individual goals for each of the Company’s named executive officers with respect to cash bonus targets for the 2018 fiscal year.
None of the named executive officers received a salary increase for the 2018 fiscal year. The named executive officers were awarded bonuses for 2017 equal to 90% of their respective previously-reported target bonus amounts for 2017.
Section 9 - Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
Exhibit Number
|
|
Description
|
10.1
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 15, 2018
|
|
|
|
NewLink Genetics Corporation
|
|
|
|
|
By:
|
/s/ John B. Henneman III
|
|
John B. Henneman III
|
Its:
|
Chief Financial Officer
|
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2024 to May 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about NewLink Genetics Corporation (NASDAQ): 0 recent articles
More Newlink Genetics Corp News Articles